New ERA in the Treatment of Dyslipidemia

PROGRAM DESCRIPTION This webcast is intended to improve care of dyslipidemia in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia by accelerating adoption of new guidelines and evidence-based practice change. In-depth ...

PROGRAM DESCRIPTION
This webcast is intended to improve care of dyslipidemia in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

EDUCATIONAL OBJECTIVES
As a result of participating in the activity, learners should be better able to: Outline risk assessment tools to identify individuals with residual atherosclerotic cardiovascular disease (ASCVD) risk such as familial hypercholesterolemia and/or statin intolerance who would benefit for PCSK9 therapyAssess the latest clinical evidence on the impact of PCSK9 inhibitors evolocumab and alirocumab on LDL-C and cardiovascular risk in patients with ASCVD, familial hypercholesterolemia

---

Write the first review

Resource tags